Diabetic Macular Edema
Conditions
Keywords
Diabetic Macular Edema, Glycemic Control
Brief summary
Does diabetic patients' glycemic control affect their response to laser and/or intravitreal injection therapy in terms of visual and anatomical outcomes.
Detailed description
To evaluate the visual and anatomical response to therapy in patients with diabetic macular edema (DME) in relation to their glycemic control. Patients with DME with central foveal thickness (CFT) \> 250µm with no proliferative disease had their glycosolated hemoglobin (HbA1c) measured at baseline and 3 months. CFT by optical coherence tomography, and best corrected visual acuity (BCVA) in logMARs were measured at baseline, 1, and 3 months. Exclusion criteria: laser or intravitreal injections within 6 months, hard exudates within 500um of the foveal center, or macular traction. Therapy included laser and intravitreal anti VEGFs. HbA1c graded as: G1=\<7%, G2= 7-7.9%, G3= 8-8.9%, G4 = \>9%; and as: low \<8%, high ≥ 8%.
Interventions
OTHERRespond to therapy for diabetic macular edema
Correlate HBA1c with visual acuity outcome to therapy.
Sponsors
Cairo University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Central foveal thickness more than 250 microns
Exclusion criteria
* Proliferative Diabetic Retinopathy. * Traction Macular Membranes * Previous Laser or intravitreal injections within 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Acuity | 3 months | Correlate baseline HBA1c to the visual outcomes. |
Countries
Egypt
Outcome results
None listed